{"nctId":"NCT03665038","briefTitle":"A Study to Assess the Safety of Brexanolone in the Treatment of Adolescent Female Participants With Postpartum Depression (PPD)","startDateStruct":{"date":"2018-09-07","type":"ACTUAL"},"conditions":["Post Partum Depression"],"count":28,"armGroups":[{"label":"Brexanolone","type":"EXPERIMENTAL","interventionNames":["Drug: Brexanolone"]}],"interventions":[{"name":"Brexanolone","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n1. Participant has had a major depressive episode that began no earlier than the third trimester and no later than the first 4 weeks following delivery, as diagnosed by Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Axis I Disorders (SCID-5).\n2. Participant is â‰¤6 months postpartum at screening.\n\nKey Exclusion Criteria:\n\n1. Active psychosis\n2. Attempted suicide during current episode of PPD\n3. Medical history of bipolar disorder, schizophrenia, and/or schizoaffective disorder.\n\nNote: Other protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"FEMALE","genderBased":true,"minimumAge":"15 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Participants With Treatment-Emergent Adverse Events (TEAEs)","description":"An adverse event (AE) is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. A TEAE is defined as an AE with onset on or after the start of study drug infusion, or any worsening of a pre-existing medical condition/AE with onset on or after the start of study drug infusion.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"3","spread":null},{"groupId":"OG002","value":"5","spread":null}]}]}]},{"type":"SECONDARY","title":"Area Under the Concentration-Time Curve (AUC) From Time Zero to 60 Hours (AUC0-60)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3694.9","spread":"397.90"},{"groupId":"OG001","value":"3516.0","spread":"562.85"}]}]}]},{"type":"SECONDARY","title":"AUC From Time Zero to Infinity (AUCinf)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4125.9","spread":"481.84"},{"groupId":"OG001","value":"3982.2","spread":"709.70"}]}]}]},{"type":"SECONDARY","title":"Maximum (Peak) Plasma Concentration (Cmax)","description":null,"paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"85.31","spread":"9.571"},{"groupId":"OG001","value":"81.66","spread":"13.528"}]}]}]},{"type":"SECONDARY","title":"Time at Maximum (Peak) Plasma Concentration (Tmax)","description":null,"paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.20","spread":null},{"groupId":"OG001","value":"52.30","spread":null}]}]}]},{"type":"SECONDARY","title":"Steady-State Drug Concentration in the Plasma During Constant-Rate Infusion (Css)","description":"Given that brexanolone is infused to steady-state plasma concentrations, the model-predicted steady-state drug concentration in the plasma during constant-rate infusion value also represents the predicted maximum plasma concentration at the highest infused dose (90 ug/kg/h).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.4","spread":null},{"groupId":"OG001","value":"79.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Average Drug Concentration in Plasma at Steady State During a Dosing Interval (Cavg)","description":"Cavg was evaluated as the time-weighted average plasma concentrations of brexanolone over the interval.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"61.59","spread":"6.639"},{"groupId":"OG001","value":"58.60","spread":"9.386"}]}]}]},{"type":"SECONDARY","title":"Half-Life of First Elimination Phase of Brexanolone (Thalf)","description":"Half-life is the time required for half of the drug to be eliminated from the serum.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.24","spread":"0.466"},{"groupId":"OG001","value":"12.55","spread":"1.096"}]}]}]},{"type":"SECONDARY","title":"Clearance of Brexanolone (CL/F)","description":"Clearance is defined as the volume of plasma from which a substance is completely removed per unit time.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.86","spread":"13.858"},{"groupId":"OG001","value":"77.88","spread":"18.026"}]}]}]},{"type":"SECONDARY","title":"Steady-State of Volume of Distribution (Vss)","description":"Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"448.1","spread":"70.34"},{"groupId":"OG001","value":"588.5","spread":"187.53"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":8},"commonTop":["Infusion site pain","Nausea","Dizziness","Sedation","Headache"]}}}